Breakthrough Study Confirms Remplir™ Superiority Over Standard US Nerve Repair Technique

Orthocell has today announced interim results from a new study demonstrating that Remplir™ delivers superior nerve regeneration, earlier return to function, and higher quality tissue restoration compared to current surgical suture techniques. 

The Suturing Study, conducted in collaboration with Orthocell’s Chief Scientific Officer and highly regarded physician, Professor Minghao Zheng, and the University of Western Australia, was commissioned by Orthocell to evaluate the impact of sutures on nerve regeneration and functional recovery in surgical repair of severed peripheral nerves.  

Interim Study Findings:  

Use of Remplir™ in nerve repair results in: 

1. Earlier return to nerve function compared to suture-only repair  
2. Superior regeneration of high-quality nerve tissue with better cellular alignment 
3. Faster restoration of protective nerve structure and blood vessel establishment  
4. No inflammatory response, and reduced scarring that can block nerve regeneration across repair sites 

Critically, the study provides the scientific evidence for Orthocell's US market expansion. 

Orthocell CEO Paul Anderson said:  

"These study results provide the scientific foundation to transform nerve repair surgery in the US market. With our sales teams now in market and first sales imminent, this clinical evidence positions us to rapidly establish Remplir™ as the new gold standard among US surgeons." 

The study results will form the cornerstone of Orthocell's US medical education strategy, supporting rapid adoption in the US$1.6 billion US nerve repair market. 

Click to read the ASX release.